[{"NetIncomeLoss_3_Q3_USD":-173771000.0,"ProceedsFromRelatedPartyDebt_3_Q3_USD":200000000.0,"MarketableSecuritiesCurrent_0_Q3_USD":32324000.0,"IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_3_Q3_USD":0.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":89715160.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":90096557.0,"CommitmentsAndContingencies_0_Q3_USD":null,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q3_USD":-17285000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":44377000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q3_USD":66600000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-30363000.0,"LiabilitiesFairValueDisclosure_0_Q3_USD":0.0,"Liabilities_0_Q3_USD":1044871000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_Q3_shares":1679338.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q3_USD":-5745000.0,"AssetsCurrent_0_Q3_USD":754027000.0,"OtherNoncashIncomeExpense_3_Q3_USD":-538000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":103387000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":49243000.0,"DueToRelatedPartiesNoncurrent_0_Q3_USD":313700000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":12650700.0,"DueToRelatedPartiesCurrent_0_Q3_USD":628000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q3_USD":1706000.0,"CommonStockSharesIssued_0_Q3_shares":90870042.0,"Assets_0_Q3_USD":774214000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3_Q3_USD":-15639000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":9669000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":713523000.0,"OtherAssetsNoncurrent_0_Q3_USD":7295000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":30453000.0,"AssetsFairValueDisclosure_0_Q3_USD":70003000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":15317000.0,"GainsLossesOnExtinguishmentOfDebt_3_Q3_USD":0.0,"GainsLossesOnExtinguishmentOfDebt_1_Q3_USD":0.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":16178000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":5891000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":-616000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":-1154000.0,"IncreaseDecreaseInDeferredRevenue_3_Q3_USD":478908000.0,"NumberOfReportableSegments_3_Q3_segment":1.0,"CommonStockValue_0_Q3_USD":2000.0,"Revenues_3_Q3_USD":34712000.0,"Revenues_1_Q3_USD":1379000.0,"IncreaseDecreaseInOtherCurrentAssets_3_Q3_USD":1309000.0,"IncreaseDecreaseInDueToRelatedPartiesCurrent_3_Q3_USD":628000.0,"EffectiveIncomeTaxRateContinuingOperations_3_Q3_pure":0.0035,"EffectiveIncomeTaxRateContinuingOperations_1_Q3_pure":0.0154,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":205284000.0,"RestrictedCash_0_Q3_USD":2987000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":18235000.0,"DeferredRevenueNoncurrent_0_Q3_USD":418344000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q3_USD":745800000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-189410000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-79594000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-5745000.0,"ShareBasedCompensation_3_Q3_USD":21746000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":10045000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.0,"CommonStockSharesOutstanding_0_Q3_shares":90870042.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":47562000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q3_shares":8221197.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3_Q3_USD":-15639000.0,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q3_USD":-5745000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-174387000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-75003000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":7010000.0,"RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_3_Q3_USD":1379000.0,"RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1_Q3_USD":1379000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":463571000.0,"LiabilitiesCurrent_0_Q3_USD":252072000.0,"DeferredRevenueCurrent_0_Q3_USD":100564000.0,"AccountsPayableCurrent_0_Q3_USD":12357000.0,"InterestExpense_3_Q3_USD":6908000.0,"InterestExpense_1_Q3_USD":2609000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":716510000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":8180000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":5284000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":2844000.0,"AdditionalPaidInCapital_0_Q3_USD":711411000.0,"StockIssuedDuringPeriodSharesStockOptionsExercised_3_Q3_shares":729024.0,"NumberOfOperatingSegments_3_Q3_segment":1.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":2847000.0,"NetIncomeLoss_1_Q3_USD":-73849000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":638492000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":115160000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-964785000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q3_shares":8221197.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":-89000.0,"IncreaseDecreaseInAccountsPayableTrade_3_Q3_USD":-2977000.0,"CommonStockSharesAuthorized_0_Q3_shares":564111242.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":33333000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":0.0,"OperatingIncomeLoss_3_Q3_USD":-183835000.0,"OperatingIncomeLoss_1_Q3_USD":-78317000.0,"ForeignCurrencyTransactionGainBeforeTax_3_Q3_USD":16178000.0,"InvestmentIncomeInterest_3_Q3_USD":178000.0,"InvestmentIncomeInterest_1_Q3_USD":32000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":774214000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":13016000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":21746000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":7010000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3_Q3_shares":452419.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":1731000.0,"OperatingExpenses_3_Q3_USD":218547000.0,"OperatingExpenses_1_Q3_USD":79696000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-1.94,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.82,"OtherLiabilitiesNoncurrent_0_Q3_USD":4662000.0,"StockholdersEquity_0_Q3_USD":-270657000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":1036000.0,"IncreaseDecreaseInOtherOperatingLiabilities_3_Q3_USD":1080000.0,"AmortizationOfFinancingCostsAndDiscounts_3_Q3_USD":40000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0_Q3_shares":4456746.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":1334000.0,"Ticker":"MYOV","CIK":"1679082","name":"MYOVANT SCIENCES LTD.","OfficialName":"Myovant Sciences Ltd. Common Shares","form":"10-Q","period":"20201231","fy":"2021.0","fp":"Q3","qtrs":"3","uom":"USD","footnote":"nan","Market Cap":"1001965304.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20210211"}]